“The ILCA Annual Conference is the leading scientific forum in the liver cancer field connecting hundreds of international participants from all related disciplines to exchange their knowledge and best practices with big idea presentations, symposia, workshops and networking sessions.”
ILCA 2022 will provide you with a 3-day cutting-edge scientific programme with a multidisciplinary and transversal approach linking research to practice to drive patient care and to impact careers.
Conference Days
Early Bird Deadline
across all liver cancer interrelated fields and increase personal knowledge and best practices
a scientific programme with the latest innovations and advancements in research and treatment levels
an impressive speaker line-up of experts in liver cancer
Highlighted sessions and networking for students and young investigators
Meet partners and learn the latest industry developments
MD, PhD, Associated Professor, Medicine, Liver Diseases, Hematology and Medical Oncology at Icahn School of Medicine at Mount Sinai, NY, USA
Augusto Villanueva is Assistant Professor in the Liver Cancer Program (Icahn School of Medicine at Mount Sinai, New York). He received his medical degree from the University of Santiago de Compostela (Spain), and he is board certified in Gastroenterology and Hepatology (Spain).
In 2013, we jointed the Institute of Liver Studies atKing’s College Hospital in London as Senior Lecturer and Consultant Hepatologist where he was co-leadingthe HCC Clinic and Multidisciplinary Tumor Board.
In 2014 he was recruitedatthe Icahn School of Medicine at Mount Sinai where he combines clinical activity and research focused on the development of novel minimally invasive biomarkers of liver cancer using liquid biopsy. He has more than 135publications (>14,000 citations, H-index 55) including articles in N Engl J Med, Nat Genet, Nat Biotech, Nat Commun,Gastroenterology, Hepatology, J Hepatol, J Clin Invest, Oncogene, etc.
He wrote more than 15 book chapters and edited a book on resistance to targeted therapies in HCC. He servedas Associate Editor for J Hepatoland Liver Cancerand he is the current Executive Secretary of the International Liver Cancer Association.
Professor of Medicine at University of Paris. Department of Oncology at the European Hospital Georges Pompidou (AP-HP)
Jessica Zucman-Rossi is Professor of Medicine at University of Paris, within the department of Oncology at the European Hospital Georges Pompidou (AP-HP). She is the director of the Cordeliers Center of Research and of the team “Functional Genomics of Solid Tumors”, with a focus on liver, mesothelial and viral induced tumors.
Her group was pioneer in the elucidation of the molecular classification of benign and malignant liver tumors. Currently, she is the President of the International Liver Cancer Association (ILCA) and she acts as Editor in Chief for the new EASL open access journal “JHEP Reports”.
Associate Professor of Medical Oncology. Director of the Residency Program in Medical Oncology, Department of Biomedical Sciences – Humanitas University. Deputy Director - Medical Oncology Unit - Humanitas Cancer Center, IRCCS Humanitas Research Hospital
Lorenza Rimassa graduated at the Medical School of the University of Milan (Italy) in 1993.Her post-graduate education continued with a Medical Oncology degree, achieved in 1997. She worked at the San Raffaele
Institute and at the National Cancer Institute in Milan, as clinical and research fellow. Since 1998 she is working at Humanitas Cancer Center, IRCCS Humanitas Research Hospital, in Milan.
She is Deputy Director of the Medical Oncology Unit and Head of the Gastrointestinal (GI) Oncology Section. Since October 2019 she is Associate Professor of Medical Oncology at Humanitas University, since April 2020 Member of Academic Board of the PhD Program in Data science in Medicine &Nutrition (DASMEN), and since November 2020 Director of the Residency Program in Medical Oncology at the same University, in Milan.
She has a long-standing interest in the field of clinical and translational cancer research, and she has been involved in more than 100 clinical trials.From 2005, she focused her interest on patients with GI cancers, treated with new drugs in national and international clinical trials.
From 2012, she is principal investigator, member of the steering committee, or of the data monitoring committee for national and international, multicenter, phase 1-2-3clinical and translational trials of new drugs-chemotherapy, small molecules, monoclonal antibodies, immuno-oncology drugs-for GI cancers, in particular hepatocellular carcinoma and biliary tract cancers.
She is a member of the Italian Association of Medical Oncology (AIOM), of the European Society for Medical Oncology (ESMO), of the American Society of Clinical Oncology (ASCO), of the European Association for the Study of the Liver (EASL), of the International Liver Cancer Association (ILCA).
She is a member of the AIOM Guidelines Writing Committee on Hepatocellular Carcinoma, of the Scientific Committee of the Italian Group for the Study of Digestive Tract Cancers (GISCAD)Foundation, of the Scientific Committee of the Suisse Liver Cancer Foundation, Chair of the ILCA Communication Committee and member of the ILCA Governing Board, and member as Special Expert of the International Trials Europe on the Hepatobiliary Task Force (HB TF) of the National Cancer Institute (NCI, Bethesda, MD, US) Gastrointestinal Steering Committee (GISC).
She is author of more than 150 articles published in peer-reviewed journals on the development of new treatments and biomarkers for GI cancers. She is Associate Editor for Liver Cancer International, and member of the Editorial Board of several journals including Journal of Hepatology, Liver International, Cancers, Journal of Hepatocellular Carcinoma, and Scientific Reports.
She is ad-hoc reviewer for several international scientific journals.
She is speaker, chair, discussant, member of the organizing and scientific committee at national and international congresses and conferences.
PhD, Assistant Professor, Faculty of Health and Medical Sciences , Copenhagen, Denmark
Monika Lewinska is a senior researcher in the Andersen’s Group at BRIC, University of Copenhagen. Her research focusses on metabolic rearrangements in primary liver cancer and metabolic diseases contributing to the PLC development.
Entertainment & technology show inspirational speakers including game changing not just a large-scale conference but a large educational hub.